Autolus Therapeutics Equity 2024

Autolus Therapeutics Aktienanalyse

What does Autolus Therapeutics do?

Autolus Therapeutics PLC is a global biopharmaceutical company dedicated to the development of novel therapies for cancer. The company was founded in 2014 by an experienced team of scientists and executives from the biotech industry with the goal of revolutionizing cancer treatment. Autolus Therapeutics' business model is to develop and market novel cancer immunotherapies. The company utilizes innovative technologies such as CAR-T cell therapy and T-cell receptor (TCR) therapy. By targeting the immune system, cancer cells can be recognized and destroyed. Autolus Therapeutics operates a complex network of different sectors and areas to ensure comprehensive development and marketing of its products. This includes research and development, manufacturing and production, as well as clinical testing and approval of therapies. Currently, Autolus Therapeutics focuses on developing therapies for various types of cancer, such as leukemia, lymphoma, and solid tumors. The company has built a broad pipeline of products and therapeutic approaches that are currently in different phases of clinical development. The main focus is on an innovative CAR-T cell therapy, in which the body's own T cells are equipped with a chimeric antigen receptor (CAR) to specifically recognize and combat cancer cells. Autolus Therapeutics' different CAR-T therapies target specific antigens expressed on tumor cells. Another important part of Autolus Therapeutics' pipeline is T-cell receptor (TCR) therapies. T cells are equipped with specific receptors to also target and destroy cancer cells. These therapeutic approaches are currently in clinical development. Autolus Therapeutics collaborates closely with other companies and institutions in the industry to further advance the development and marketing of cancer therapies. This includes strategic partnerships with major pharmaceutical companies such as AstraZeneca and Bluebird Bio. The history of Autolus Therapeutics is characterized by rapid growth and high innovation. Shortly after its founding, the company was able to secure significant funding rounds and international partners. In the following years, the pipeline was further expanded, and the first clinical trials were initiated. Currently, Autolus Therapeutics employs over 250 people at locations in the United Kingdom and the United States. The company has a market capitalization of around $1.5 billion and is considered one of the most promising companies in the biopharmaceutical industry. In summary, Autolus Therapeutics is an innovative and ambitious company dedicated to the research and development of novel cancer therapies. The broad pipeline of products and therapeutic approaches, as well as the close partnerships in the industry, give hope for a promising future of the company. Autolus Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Autolus Therapeutics's Equity

Autolus Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Autolus Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Autolus Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Autolus Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Autolus Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Autolus Therapeutics stock

What is the equity of Autolus Therapeutics this year?

Autolus Therapeutics has equity of 111.47 M USD this year.

What was the equity of Autolus Therapeutics compared to the previous year?

The equity of Autolus Therapeutics has increased/decreased by -62.68% decreased compared to the previous year.

What impact does a high equity have on investors of Autolus Therapeutics?

A high equity is advantageous for investors of Autolus Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Autolus Therapeutics?

A low equity can be a risk for investors of Autolus Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Autolus Therapeutics affect the company?

An increase in equity of Autolus Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Autolus Therapeutics affect the company?

A reduction in equity of Autolus Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Autolus Therapeutics?

Some factors that can affect the equity of Autolus Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Autolus Therapeutics so important for investors?

The equity of Autolus Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Autolus Therapeutics take to change the equity?

To change equity, Autolus Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Autolus Therapeutics pay?

Over the past 12 months, Autolus Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Autolus Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Autolus Therapeutics?

The current dividend yield of Autolus Therapeutics is .

When does Autolus Therapeutics pay dividends?

Autolus Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Autolus Therapeutics?

Autolus Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Autolus Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Autolus Therapeutics located?

Autolus Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Autolus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Autolus Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Autolus Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Autolus Therapeutics in the year 2023?

In the year 2023, Autolus Therapeutics distributed 0 USD as dividends.

In which currency does Autolus Therapeutics pay out the dividend?

The dividends of Autolus Therapeutics are distributed in USD.